

Robert Campbell Tait

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9499682/publications.pdf>

Version: 2024-02-01

160
papers

8,656
citations

50276

46
h-index

45317

90
g-index

163
all docs

163
docs citations

163
times ranked

7046
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines on the investigation and management of antiphospholipid syndrome. British Journal of Haematology, 2012, 157, 47-58.	2.5	492
2	Guidelines on oral anticoagulation with warfarin – fourth edition. British Journal of Haematology, 2011, 154, 311-324.	2.5	482
3	Clinical guidelines for testing for heritable thrombophilia. British Journal of Haematology, 2010, 149, 209-220.	2.5	434
4	Risk Factors for Pregnancy Associated Venous Thromboembolism. Thrombosis and Haemostasis, 1997, 78, 1183-1188.	3.4	358
5	Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). Journal of Thrombosis and Haemostasis, 2012, 10, 1019-1025.	3.8	353
6	Prevalence of antithrombin deficiency in the healthy population. British Journal of Haematology, 1994, 87, 106-112.	2.5	346
7	The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology. British Journal of Haematology, 2014, 167, 453-465.	2.5	297
8	Prevalence of Protein C Deficiency in the Healthy Population. Thrombosis and Haemostasis, 1995, 73, 087-093.	3.4	270
9	Systematic Review: D-Dimer to Predict Recurrent Disease after Stopping Anticoagulant Therapy for Unprovoked Venous Thromboembolism. Annals of Internal Medicine, 2008, 149, 481.	3.9	234
10	Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ: British Medical Journal, 2011, 342, d813-d813.	2.3	218
11	Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia, 2008, 14, 671-684.	2.1	206
12	Development of resistance to activated protein C during pregnancy. British Journal of Haematology, 1995, 90, 725-727.	2.5	201
13	Guideline on the management of bleeding in patients on antithrombotic agents. British Journal of Haematology, 2013, 160, 35-46.	2.5	197
14	A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. British Journal of Haematology, 2001, 113, 636-641.	2.5	195
15	Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. Journal of Thrombosis and Haemostasis, 2010, 8, 2436-2442.	3.8	181
16	Perioperative management of anticoagulation and antiplatelet therapy. British Journal of Haematology, 2016, 175, 602-613.	2.5	159
17	Patient-Level Meta-analysis: Effect of Measurement Timing, Threshold, and Patient Age on Ability of D-Dimer Testing to Assess Recurrence Risk After Unprovoked Venous Thromboembolism. Annals of Internal Medicine, 2010, 153, 523.	3.9	149
18	Hereditary and Acquired Antithrombin Deficiency. Drugs, 2007, 67, 1429-1440.	10.9	144

#	ARTICLE	IF	CITATIONS
19	Guideline on aspects of cancer-related venous thrombosis. British Journal of Haematology, 2015, 170, 640-648.	2.5	139
20	Randomized controlled trial of homocysteine-lowering vitamin treatment in elderly patients with vascular disease. American Journal of Clinical Nutrition, 2005, 82, 1320-1326.	4.7	129
21	'Last-ditch' use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sanguinis, 2004, 86, 120-124.	1.5	122
22	Guidelines on the investigation and management of venous thrombosis at unusual sites. British Journal of Haematology, 2012, 159, 28-38.	2.5	119
23	Phenotypic Characterization of <i>EIF2AK4</i> Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. Circulation, 2017, 136, 2022-2033.	1.6	111
24	Changing patterns of bleeding in patients with severe haemophilia A. Haemophilia, 2009, 15, 1210-1214.	2.1	109
25	Dementia in subjects with atrial fibrillation: hemostatic function and the role of anticoagulation. Journal of Thrombosis and Haemostasis, 2004, 2, 1873-1878.	3.8	102
26	Management of oral anticoagulant-induced intracranial haemorrhage. Blood Reviews, 1998, 12, 35-44.	5.7	101
27	Oral Anticoagulation and Hemorrhagic Complications in an Elderly Population With Atrial Fibrillation. Archives of Internal Medicine, 2001, 161, 2125.	3.8	99
28	The role of hepatitis C virus in the aetiology of non-Hodgkins lymphoma-A regional association?. Leukemia and Lymphoma, 1997, 26, 127-130.	1.3	88
29	Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2019, 321, 56.	7.4	88
30	Prevalence of the post-thrombotic syndrome in young women with previous venous thromboembolism. British Journal of Haematology, 2000, 108, 272-274.	2.5	82
31	Restarting anticoagulation in prosthetic heart valve patients after intracranial haemorrhage: a 2-year follow-up. British Journal of Haematology, 1998, 103, 1064-1066.	2.5	77
32	Prothrombin 20210 GA, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy. BJOG: an International Journal of Obstetrics and Gynaecology, 2000, 107, 565-569.	2.3	74
33	Increased prevalence of hypertension in haemophilia patients. Thrombosis and Haemostasis, 2012, 108, 750-755.	3.4	66
34	The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. Emergency Medicine Journal, 2014, 31, 163-168.	1.0	64
35	Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patients. Thrombosis and Haemostasis, 2013, 109, 16-23.	3.4	62
36	British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism (PE). Thorax, 2018, 73, ii1-ii29.	5.6	58

#	ARTICLE	IF	CITATIONS
37	Subclinical pulmonary function defects following autologous and allogeneic bone marrow transplantation: Relationship to total body irradiation and graft-versus-host disease. International Journal of Radiation Oncology Biology Physics, 1991, 20, 1219-1227.	0.8	57
38	Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data. Journal of Thrombosis and Haemostasis, 2015, 13, 775-781.	3.8	57
39	Risk factors for pregnancy associated venous thromboembolism. Thrombosis and Haemostasis, 1997, 78, 1183-8.	3.4	57
40	Influence of demographic factors on antithrombin III activity in a healthy population. British Journal of Haematology, 1993, 84, 476-480.	2.5	56
41	A warfarin induction regimen for out-patient anticoagulation in patients with atrial fibrillation. British Journal of Haematology, 1998, 101, 450-454.	2.5	55
42	Injecting drug use is a risk factor for deep vein thrombosis in women in Glasgow. British Journal of Haematology, 2001, 112, 641-643.	2.5	55
43	Applicability of the European Society of Cardiology guidelines on management of acute coronary syndromes to people with haemophilia - an assessment by the ADVANCE Working Group. Haemophilia, 2013, 19, 833-840.	2.1	52
44	The prevalence of, and molecular defects underlying, inherited protein S deficiency in the general population. British Journal of Haematology, 2004, 125, 647-654.	2.5	51
45	A prospective randomized study to determine the optimal dose of intravenous vitamin K in reversal of over-warfarinization. British Journal of Haematology, 2000, 109, 537-539.	2.5	50
46	Isolated Familial Plasminogen Deficiency May not Be a Risk Factor for Thrombosis. Thrombosis and Haemostasis, 1996, 76, 1004-1008.	3.4	49
47	Antithrombin Cambridge II, 384 Ala to Ser Further evidence of the role of the reactive centre loop in the inhibitory function of the serpins. FEBS Letters, 1991, 285, 248-250.	2.8	46
48	Flow cytometry in diagnosis and management of large fetomaternal haemorrhage.. Journal of Clinical Pathology, 1995, 48, 1005-1008.	2.0	46
49	Rare variants in GP1BB are responsible for autosomal dominant macrothrombocytopenia. Blood, 2017, 129, 520-524.	1.4	42
50	Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin international normalized R ² control and bleeding rates. British Journal of Haematology, 2012, 158, 256-261.	2.5	41
51	Analysis of natural killer effector and suppressor activity by intraepithelial lymphocytes from mouse small intestine. Clinical and Experimental Immunology, 1983, 52, 191-8.	2.6	41
52	Hypertension, haematuria and renal functioning in haemophilia – a cross-sectional study in Europe. Haemophilia, 2016, 22, 248-255.	2.1	39
53	Combined prednisolone and intravenous immunoglobulin treatment for acquired factor VIII inhibitors: a 2-year review. Haemophilia, 2001, 7, 160-163.	2.1	38
54	Vitamin B12 deficiency following restorative proctocolectomy. Colorectal Disease, 2007, 9, 562-566.	1.4	38

#	ARTICLE	IF	CITATIONS
55	Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations. <i>Thrombosis and Haemostasis</i> , 2008, 99, 616-622.	3.4	37
56	Coagulation and Fibrinolytic Activity of Tenecteplase and Alteplase in Acute Ischemic Stroke. <i>Stroke</i> , 2015, 46, 3543-3546.	2.0	37
57	Platelet and cardiac function in Darier's disease. <i>Clinical and Experimental Dermatology</i> , 2001, 26, 696-699.	1.3	36
58	De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with Seizures. <i>American Journal of Human Genetics</i> , 2018, 103, 144-153.	6.2	36
59	Superficial Vein Thrombosis: Incidence in Association with Pregnancy and Prevalence of Thrombophilic Defects. <i>Thrombosis and Haemostasis</i> , 1998, 79, 741-742.	3.4	34
60	Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome. <i>Blood</i> , 2020, 136, 1956-1967.	1.4	34
61	Oral anticoagulation in paediatric patients: dose requirements and complications.. <i>Archives of Disease in Childhood</i> , 1996, 74, 228-231.	1.9	33
62	Noonan syndrome: coagulation and clinical aspects. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 1996, 85, 1181-1185.	1.5	33
63	History of non-fatal cardiovascular disease in a cohort of Dutch and British patients with haemophilia. <i>European Journal of Haematology</i> , 2012, 89, 336-339.	2.2	32
64	A three-year prospective study of the presentation and clinical outcomes of major bleeding episodes associated with oral anticoagulant use in the UK (ORANGE study). <i>Haematologica</i> , 2018, 103, 738-745.	3.5	30
65	Plasma protein Z deficiency is common in women with antiphospholipid antibodies. <i>British Journal of Haematology</i> , 2003, 120, 913-914.	2.5	29
66	The prevalence of the cysteine1584 variant of von Willebrand factor is increased in type 1 von Willebrand disease: co-segregation with increased susceptibility to ADAMTS13 proteolysis but not clinical phenotype. <i>British Journal of Haematology</i> , 2005, 128, 830-836.	2.5	28
67	ANTITHROMBIN III ACTIVITY IN HEALTHY BLOOD DONORS: AGE AND SEX RELATED CHANGES AND THE PREVALENCE OF ASYMPTOMATIC DEFICIENCY. <i>British Journal of Haematology</i> , 1990, 75, 141-142.	2.5	27
68	Characteristics of Monoclonal Immunoglobulins That Interfere with Serum Inorganic Phosphate Measurement. <i>Annals of Clinical Biochemistry</i> , 1994, 31, 249-254.	1.6	27
69	Sex difference in the risk of recurrent venous thrombosis: a detailed analysis in four European cohorts. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1815-1822.	3.8	27
70	Unilateral wheeze caused by pseudomembranous aspergillus tracheobronchitis in the immunocompromised patient.. <i>Thorax</i> , 1993, 48, 1285-1287.	5.6	24
71	Low thrombosis rate seen in blood donors and their relatives with inherited deficiencies of antithrombin and protein C. <i>Blood Coagulation and Fibrinolysis</i> , 1996, 7, 689-694.	1.0	24
72	Anticoagulation with warfarin downregulates inflammation. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 1838-1839.	3.8	22

#	ARTICLE	IF	CITATIONS
73	Hepatitis C virus infection in patients with lymphoproliferative disorders. British Journal of Haematology, 1996, 92, 771-3.	2.5	22
74	Antithrombin Cambridge II (Ala384Ser): Clinical, Functional and Haplotype Analysis of 18 Families. Thrombosis and Haemostasis, 1998, 79, 249-253.	3.4	21
75	An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events. Leukemia and Lymphoma, 2016, 57, 2568-2574.	1.3	21
76	Diagnosis of APC resistance during pregnancy. British Journal of Haematology, 1996, 92, 1026-1027.	2.5	20
77	Stenotrophomonas Maltophilia: An Increasing Problem in Patients with Acute Leukaemia. Leukemia and Lymphoma, 1999, 35, 207-211.	1.3	20
78	Perioperative and peripartum prevention of venous thromboembolism in patients with hereditary antithrombin deficiency using recombinant antithrombin therapy. Blood Coagulation and Fibrinolysis, 2014, 25, 444-450.	1.0	18
79	Late spontaneous recovery of chronic thrombocytopenia.. Archives of Disease in Childhood, 1993, 68, 680-681.	1.9	17
80	Interaction between hormone replacement therapy preparations and oral anticoagulant therapy. BJOG: an International Journal of Obstetrics and Gynaecology, 2003, 110, 777-779.	2.3	17
81	A K19E missense mutation in the plasminogen gene is a common cause of familial hypoplasminogenaemia. Blood Coagulation and Fibrinolysis, 2003, 14, 411-416.	1.0	17
82	British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism. BMJ Open Respiratory Research, 2018, 5, e000281.	3.0	16
83	Low-Dose Alteplase During Primary Percutaneous Coronary Intervention According to Ischemic Time. Journal of the American College of Cardiology, 2020, 75, 1406-1421.	2.8	16
84	A new pedigree with thrombomodulin-associated coagulopathy in which delayed fibrinolysis is partially attenuated by co-inherited TAFI deficiency. Journal of Thrombosis and Haemostasis, 2020, 18, 2209-2214.	3.8	16
85	Obstructive Uropathy and Vesicovaginal Fistula Secondary to a Retained Sex Toy in the Vagina. Journal of Sexual Medicine, 2014, 11, 2595-2600.	0.6	15
86	Haematological management of major bleeding associated with direct oral anticoagulants – UK experience. British Journal of Haematology, 2019, 185, 514-522.	2.5	15
87	Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study. Blood Advances, 2022, 6, 902-908.	5.2	15
88	Use of Recombinant Activated Factor VII for Bleeding in Pancreatitis. Pancreas, 2005, 30, 279-284.	1.1	14
89	Molecular characterization of 11 novel mutations in patients with heterozygous and homozygous FV deficiency. Haemophilia, 2010, 16, 937-942.	2.1	14
90	Waldenstrom's macroglobulinaemia secreting a paraprotein with lupus anticoagulant activity: possible association with gastrointestinal tract disease and malabsorption.. Journal of Clinical Pathology, 1993, 46, 678-680.	2.0	13

#	ARTICLE	IF	CITATIONS
91	Age Related Changes in Protein C Activity in Healthy Adult Males. <i>Thrombosis and Haemostasis</i> , 1991, 65, 326-327.	3.4	13
92	The elevated prevalence of risk factors for chronic liver disease among ageing people with hemophilia and implications for treatment. <i>Medicine (United States)</i> , 2018, 97, e12551.	1.0	12
93	Isolated familial plasminogen deficiency may not be a risk factor for thrombosis. <i>Thrombosis and Haemostasis</i> , 1996, 76, 1004-8.	3.4	12
94	Asymptomatic coinheritance of heterozygous plasminogen deficiency and the factor VLeiden mutation. <i>Blood Coagulation and Fibrinolysis</i> , 1997, 8, 195-199.	1.0	11
95	Characterization of plasminogen variants in healthy subjects and plasminogen mutants in patients with inherited plasminogen deficiency by isoelectric focusing gel electrophoresis. <i>Thrombosis and Haemostasis</i> , 2004, 92, 352-357.	3.4	11
96	Immediate haemostasis with recombinant factor VIIa for haemorrhage following Hickman line insertion in acute myeloid leukaemia. <i>International Journal of Laboratory Hematology</i> , 2004, 26, 229-231.	0.2	11
97	<i>F8</i> and <i>F9</i> mutations fail to coâ€segregate in a family with coâ€incident haemophilia A and B. <i>Haemophilia</i> , 2011, 17, e230-4.	2.1	11
98	Patient-level compared with study-level meta-analyses demonstrate consistency of D-dimer as predictor of venous thromboembolic recurrences. <i>Journal of Clinical Epidemiology</i> , 2013, 66, 415-425.	5.0	11
99	Correlating prothrombin time with plasma rivaroxaban level. <i>British Journal of Haematology</i> , 2013, 163, 685-687.	2.5	11
100	<scp>FVIII</scp> inhibitor development according to concentrate: data from the <scp>EUHASS</scp> registry excluding overlap with other studies. <i>Haemophilia</i> , 2016, 22, e36-8.	2.1	11
101	Effects of Intracoronary Alteplase on Microvascular Function in Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2020, 9, e014066.	3.7	11
102	A two-phase audit of fresh frozen plasma: a regional approach. <i>Transfusion Medicine</i> , 2004, 14, 75-76.	1.1	10
103	Quality and predictors of anticoagulant control with vitamin K antagonist for stroke prevention in atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2016, 116, 578-580.	3.4	10
104	Influence of Genotype on Warfarin Maintenance Dose Predictions Produced Using a Bayesian Dose Individualization Tool. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 677-683.	2.0	10
105	How to compare cardiovascular disease and risk factors in elderly patients with haemophilia with the general population. <i>Haemophilia</i> , 2016, 22, e406-16.	2.1	9
106	A Joint Model for Vitamin K-Dependent Clotting Factors and Anticoagulation Proteins. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1555-1566.	3.5	9
107	Are Atrial Fibrillation Guidelines Altering Management? A Community Based Study. <i>Scottish Medical Journal</i> , 2005, 50, 166-169.	1.3	8
108	Hepatitis C infection and outcomes in the Scottish haemophilia population. <i>Haemophilia</i> , 2013, 19, 870-875.	2.1	8

#	ARTICLE	IF	CITATIONS
109	A Novel, Enriched Population Pharmacokinetic Model for Recombinant Factor VIII-Fc Fusion Protein Concentrate in Hemophilia A Patients. <i>Thrombosis and Haemostasis</i> , 2020, 120, 747-757.	3.4	8
110	Coeliac disease presenting as variceal haemorrhage. <i>Gut</i> , 2003, 52, 758-758.	12.1	8
111	Two novel antithrombin variants, Asn187Asp and Asn187Lys, indicate a functional role for asparagine 187. <i>Blood Coagulation and Fibrinolysis</i> , 1995, 6, 51-54.	1.0	7
112	Restarting Oral Anticoagulation After Intracranial Hemorrhage. <i>Stroke</i> , 2004, 35, e5-6; author reply e5-6.	2.0	7
113	Hematuria in aging men with hemophilia: Association with factor prophylaxis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 309-317.	2.3	7
114	Protein S deficiency after varicella. <i>Journal of Pediatrics</i> , 1996, 129, 315.	1.8	6
115	A novel, biodegradable and reversible polyelectrolyte platform for topical-colonic delivery of pentosan polysulphate. <i>International Journal of Pharmaceutics</i> , 2011, 404, 124-132.	5.2	6
116	Macroscopic hematuria as a risk factor for hypertension in ageing people with hemophilia and a family history of hypertension. <i>Medicine (United States)</i> , 2020, 99, e19339.	1.0	6
117	Effect of coronary flow on intracoronary alteplase: a prespecified analysis from a randomised trial. <i>Heart</i> , 2021, 107, 299-312.	2.9	6
118	Plasminogen levels in healthy volunteers–influence of age, sex, smoking and oral contraceptives. <i>Thrombosis and Haemostasis</i> , 1992, 68, 506-10.	3.4	6
119	Protein C activity in healthy volunteers–influence of age, sex, smoking and oral contraceptives. <i>Thrombosis and Haemostasis</i> , 1993, 70, 281-5.	3.4	6
120	Superficial vein thrombosis: incidence in association with pregnancy and prevalence of thrombophilic defects. <i>Thrombosis and Haemostasis</i> , 1998, 79, 741-2.	3.4	6
121	Spontaneous sublingual haematoma in acquired haemophilia: case report. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2017, 55, e17-e18.	0.8	5
122	Diagnosis of APC resistance during pregnancy. <i>British Journal of Haematology</i> , 1996, 92, 1026-1027.	2.5	5
123	Toxoplasmosis after BMT for CML. <i>Bone Marrow Transplantation</i> , 1990, 5, 65-6.	2.4	5
124	Antithrombin cambridge II (Ala384Ser): clinical, functional and haplotype analysis of 18 families. <i>Thrombosis and Haemostasis</i> , 1998, 79, 249-53.	3.4	5
125	Activated protein C resistance in normal pregnancy. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1998, 105, 1129-1130.	2.3	4
126	Successful elimination of factor VIII inhibitor using Cyclosporin A. <i>British Journal of Haematology</i> , 2003, 122, 1024-1025.	2.5	3

#	ARTICLE	IF	CITATIONS
127	Antithrombin-Î± for the prophylaxis of venous thrombosis in congenital antithrombin deficiency. Expert Review of Hematology, 2009, 2, 499-507.	2.2	3
128	Hemostasis and Anticoagulants. , 2014, , 479-496.		3
129	Predicting Disease Recurrence in Patients with Previous Unprovoked Venous Thromboembolism: The DASH Prediction Score. Blood, 2011, 118, 544-544.	1.4	3
130	Activated protein C resistance in normal pregnancy. BJOG: an International Journal of Obstetrics and Gynaecology, 1998, 105, 473-474.	2.3	2
131	Hysterectomy techniques and their effect on the blood markers of thrombogenicity. Gynaecological Endoscopy, 2000, 9, 379-383.	0.4	2
132	Treatment of acquired haemophilia. Internal Medicine Journal, 2002, 32, 625-626.	0.8	2
133	Performance of the LumiraDx Platform INR Test in an Anticoagulation Clinic Point-of-Care Setting Compared With an Established Laboratory Reference Method. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961989042.	1.7	2
134	Clinical and radiological characteristics of acute pulmonary embolus in relation to 28-day and 6-month mortality. PLoS ONE, 2021, 16, e0258843.	2.5	2
135	Acquired activated protein C resistance in pregnancy is not due to elevated plasma caeruloplasmin levels. British Journal of Haematology, 1999, 105, 1149-1150.	2.5	1
136	Low-molecular-weight heparin as optimal solution to therapeutic heparinization. American Heart Journal, 2000, 139, 558-560.	2.7	1
137	Reversal of asymptomatic over-anticoagulation with oral vitamin K. British Journal of Haematology, 2006, 135, 591-592.	2.5	1
138	C0353 United Kingdom consensus based practical guide for the management of haemorrhage in patients receiving dabigatran. Thrombosis Research, 2012, 130, S114-S115.	1.7	1
139	Oral anticoagulant agentâ€associated bleeding events reporting system (<scp>ORANGE</scp>) study. British Journal of Haematology, 2014, 167, 274-276.	2.5	1
140	Correction of international normalised ratio in major bleeding related to vitamin K antagonists is associated with better survival: A UK study. Thrombosis Research, 2021, 197, 153-159.	1.7	1
141	Antithrombin Alfa in Hereditary Antithrombin Deficient Patients at High Risk for Thromboembolic Complications. Blood, 2008, 112, 986-986.	1.4	1
142	Renal Status and Hematuria in Older Patients with Hemophilia. Blood, 2015, 126, 2290-2290.	1.4	1
143	Interaction between hormone replacement therapy preparations and oral anticoagulant therapy. BJOG: an International Journal of Obstetrics and Gynaecology, 2003, 110, 777-9.	2.3	1
144	Natural anticoagulants in smokers. American Heart Journal, 1993, 125, 1806.	2.7	0

#	ARTICLE	IF	CITATIONS
145	P1. Diagnosis of APC resistance during pregnancy. Blood Coagulation and Fibrinolysis, 1996, 7, 388.	1.0	0
146	P25. Clinical reliability of the PT-derived fibrinogen assay. Blood Coagulation and Fibrinolysis, 1996, 7, 398.	1.0	0
147	Superficial vein thrombosis. Blood Coagulation and Fibrinolysis, 1997, 8, 462.	1.0	0
148	ANTITHROMBIN CONCENTRATE ALONE MAY NOT PREVENT VENOUS THROMBOEMBOLISM FOLLOWING NEUROSURGERY. British Journal of Haematology, 1998, 103, 583-584.	2.5	0
149	Blood Ordering Practices in Elective and Emergency Surgical Procedures. Scottish Medical Journal, 1998, 43, 154-155.	1.3	0
150	Authors'™ reply: Vitamin B12 deficiency following restorative proctocolectomy (Colorectal Dis. 2007) Tj ETQq0 0.0 rgBT /Oyerlock 10	1.4	0
151	Evaluation of the effects of single-nucleotide polymorphisms in CYP3A4 and CYP4F2 on stable phenprocoumon and acenocoumarol maintenance doses: comment. Journal of Thrombosis and Haemostasis, 2014, 12, 1196-1197.	3.8	0
152	Individual and monitoring centre influences upon anticoagulation control of <scp>AF</scp> patients on warfarin: A longitudinal multi-centre <scp>UK</scp>-based study. European Journal of Haematology, 2018, 101, 486-495.	2.2	0
153	TCT CONNECT-16 Implications of Impaired Coronary Flow on the Effects of Intracoronary Alteplase During Primary Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2020, 76, B7-B8.	2.8	0
154	New Inhibitors in the Ageing Population: A retrospective, observational, cohort study of new inhibitors in older people with haemophilia. Thrombosis and Haemostasis, 2021, , .	3.4	0
155	P24. Value of a negative D-dimer result in the evaluation of suspected acute pulmonary embolism: The Glasgow Royal Infirmary experience. Nuclear Medicine Communications, 2002, 23, 412-413.	1.1	0
156	Identification of Ten Novel Mutations Associated with Inherited Coagulation Factor V Deficiency.. Blood, 2004, 104, 1030-1030.	1.4	0
157	Low-dose intracoronary alteplase during primary percutaneous coronary intervention in patients with acute myocardial infarction: the T-TIME three-arm RCT. Efficacy and Mechanism Evaluation, 2020, 7, 1-86.	0.7	0
158	Anticoagulation in patients with thromboembolic disease. Thorax, 2001, 56 Suppl 2, ii30-7.	5.6	0
159	History of the West of Scotland Haemophilia Centre, Glasgow, 1950-2019. Journal of the Royal College of Physicians of Edinburgh, The, 2020, 50, 330-338.	0.6	0
160	Age related changes in protein C activity in healthy adult males. Thrombosis and Haemostasis, 1991, 65, 326-7.	3.4	0